Acetic Acid

Acetic Acid

SCHEMBL524136

CC(=O)O.CC(=O)O.O=C(O)CCC(O)CO

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 3/20 0.46
KDM4A O75164 2/20 0.46
KDM4C Q9H3R0 2/20 0.46
KDM2A Q9Y2K7 2/20 0.46
TET3 O43151 1/20 0.46
GABRP O00591 2/20 0.44
GABRD O14764 2/20 0.44
GABRA1 P14867 2/20 0.44
GABRB1 P18505 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA5 P31644 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44
GABRB2 P47870 2/20 0.44
GABRA4 P48169 2/20 0.44
GABRE P78334 2/20 0.44
GABRA6 Q16445 2/20 0.44
GABRG1 Q8N1C3 2/20 0.44
GABRG3 Q99928 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL5857865 1.00 TET2 (0.46) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL326464 0.93
SCHEMBL8655218 0.93
SCHEMBL23927578 0.93
Bicarbonate SCHEMBL9800960 0.90 TET2 (0.50) TET2KDM4AKDM4CKDM2ATET3
Water SCHEMBL6694857 0.90 TET2 (0.50) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL30994572 0.82 MEN1 (0.44) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL9302022 0.81 TET2 (0.46) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL3056607 0.80
SCHEMBL30266672 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11918550-B2 Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-03-05 US claimed
US-20230338322-A1 GLYCERYLTRIACETATE (GTA) FOR USE IN IMPROVING BREATHING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-10-26 US claimed
US-11684601-B2 Treatment of cancer with combinations of agents THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-06-27 US claimed
EP-4146189-A1 GLYCERYLTRIACETATE (GTA) FOR USE IN IMPROVING BREATHING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2023-03-15 EP claimed
US-20220175704-A1 SENSITIZATION OF CANCER CELLS TO DIFFERENTIATION THERAPY WITH MITOCHONDRIAL UNCOUPLER NICLOSAMIDE ETHANOLAMINE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-06-09 US claimed
WO-2021224912-A1 GLYCERYLTRIACETATE (GTA) FOR USE IN IMPROVING BREATHING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2021-11-11 WO claimed
US-10765654-B2 Methods and compounds for treating cancer UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2020-09-08 US claimed
US-20200261393-A1 TREATMENT OF CANCER WITH COMBINATIONS OF AGENTS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-08-20 US claimed
WO-2019180604-A1 A SET OF DISPERSIBLE FORMULATIONS FOR TRAINING TO USE A POTTY OR A DRY BOTTOM TOILET FOR EXCRETION SOUCKOVA DANIELA (CZ) 2019-09-26 WO claimed
EP-1691746-B1 MUCOADHESIVE DRUG DELIVERY DEVICES AND METHODS OF MAKING AND USING THEREOF GEL DEL TECHNOLOGIES INC (US) 2015-05-27 EP claimed
WO-2004100883-A2 METHOD FOR PREPARING THERMOFORMED COMPOSITIONS CONTAINING ACRYLIC POLYMER BINDERS, PHARMACEUTUAL DOSAGE FORMS AND METHODS OF PREPARING THE SAME BPSI HOLDINGS, INC. (US) 2004-11-25 WO claimed
WO-2004010984-A2 MICROCAPSULES WITH MODIFIED RELEASE OF ACTIVE PRINCIPLES WITH LOW SOLUBILITY FOR ORAL DELIVERY FLAMEL TECHNOLOGIES (FR) 2004-02-05 WO claimed
WO-2004010983-A2 ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A PLURALITY OF MICROCAPSULES FOR PROLONGED RELEASE OF ACTIVE PRINCIPLE(S) WITH LOW SOLUBILITY FLAMEL TECHNOLOGIES (FR) 2004-02-05 WO claimed
EP-1272165-A1 ACRYLIC ENTERIC COATING COMPOSITIONS BPSI Holdings, Inc. (US) 2003-01-08 EP claimed
US-6420473-B1 ENTERIC FILM COATED POWDER BPSI HOLDINGS, INC. 2002-07-16 US claimed
US-20010022972-A1 Acrylic enteric coating compositions ROHM GMBH (DE) 2001-09-20 US claimed
WO-2001058429-A1 ACRYLIC ENTERIC COATING COMPOSITIONS BPSI HOLDINGS, INC. (US) 2001-08-16 WO claimed
US-6001341-A Deodorant and/or antiperspirant cosmetic compositions CONDEA AUGUSTA S.P.A. (IT) 1999-12-14 US claimed
EP-0605694-B1 PROCESS FOR PRODUCING CERAMIC GREEN BODIES GAUCKLER LUDWIG J (CH) 1996-03-27 EP claimed
US-4956404-A POLYVINYL ACETATE BLEND WITH DEXTRIN, A GLYCEROL TRIESTER, AN EPOXIDIZED OIL, FUMED SILICA AND HYDROGENATED STARCH HYDROLYZA TES PELZIG JOSEF (US) 1990-09-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175704-A1 SENSITIZATION OF CANCER CELLS TO DIFFERENTIATION THERAPY WITH MITOCHONDRIAL UNCOUPLER NICLOSAMIDE ETHANOLAMINE RARS2, NME4, ALDH2 TET2 574/4885KDM4A 1770/4885KDM4C 2472/4885
US-10765654-B2 Methods and compounds for treating cancer UGCG, LPCAT1, MGMT TET2 195/4885KDM4A 267/4885KDM4C 127/4885
US-20230338322-A1 GLYCERYLTRIACETATE (GTA) FOR USE IN IMPROVING BREATHING GDA, GMPS, GGT1 TET2 2590/4885KDM4A 4152/4885KDM4C 4295/4885
US-11918550-B2 Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine RARS2, NME4, ALDH2 TET2 574/4885KDM4A 1770/4885KDM4C 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.